This site is intended for healthcare professionals

FDA accepts filing sNDA for Tyvaso inhaled solution for the treatment of pulmonary hypertension associated with interstitial lung disease .- United Therapeutics

Read time: 1 mins
Last updated:18th Aug 2020
Published:18th Aug 2020
Condition: Pulmonary Arterial Hypertension/ PH + ILD
Type: drug
Register free for full access to